TriasMD Acquires Pinnacle Surgery Center to Bring DISC
TriasMD, a musculoskeletal management company and parent of the DISC Surgery Centers, has announced its acquisition of Walnut Creek-based Pinnacle Surgery Center ("Pinnacle").
Latest Press Releases
The 'Press Releases' section offers the latest product-specific and company-related updates to our esteemed clients, providing them with a valuable resource. Members can leverage this platform for quick, efficient, and effective visibility.
— Our press release programs complement our content distribution initiatives, ensuring strong positioning across major media outlets and social media channels. This enhances the visibility of your message within the global pharmaceutical industry.
— Our press release programs complement our content distribution initiatives, ensuring strong positioning across major media outlets and social media channels. This enhances the visibility of your message within the global pharmaceutical industry.
Empaveli is the first treatment for PNH that binds to the complement protein C3
Pint Pharma and OrphanDC announced on July 25th that ANVISA, the National Health Surveillance Agency, approved, on July 25th, 2023, the drug EMPAVELI® (pegcetacoplan, indicated for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH)). Empaveli is the first treatment for PNH that binds to the complement protein C3.
Successful Launch of JVM's Next-Generation Automated Drug Dispensing System
A state-of-the-art, next-generation automated drug dispensing machine equipped with a robotic arm, independently developed by JVM, an affiliate of Hanmi Science, was successfully launched in the European market.
Alimentiv Inc. Announces New Scientific Advisors Leading Research In GI-Related Therapeutics
Alimentiv Inc. ("Alimentiv"), a leading Contract Research Organization focused on GI-related therapeutics, is pleased to announce the addition of new scientific advisors to its scientific advisory board.
CARsgen's CAR-GPC3 T-cell Therapy for Advanced Hepatocellular Carcinoma: Two Patients Achieved over 7 Years of Disease-free Survival
CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announced the publication of two cases of long-term disease-free survival in the treatment of advanced hepatocellular carcinoma (HCC) with CARsgen's innovative CAR-GPC3 T-cell therapy.
Cambrex Completes $38 Million Capacity Expansion in High Point, North Carolina
Cambrex announced the completion of its $38 million capacity expansion at its small molecule active pharmaceutical ingredient (API) manufacturing facility in High Point, North Carolina.
Deka Biosciences Closes USD $20 Million Series B2 Financing Led by MPM BioImpact
Maryland-based biotech company Deka Biosciences ("Deka") announced that it has successfully closed a USD $20 Million Series B2 financing with a syndicate of life science investors led by MPM BioImpact, and joined by additional investors including Leaps by Bayer, Lumira Ventures, O-Bio (Echo Investment Capital), Viva BioInnovator, Alexandria Venture Investments, Amana Investments, Plains Ventures, ATEM Capital and CEO John Mumm.
'LEQEMBI® Intravenous Infusion' approved for the treatment of Alzheimer's disease in Japan
BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced that "LEQEMBI® Intravenous Infusion" (200 mg, 500mg, lecanemab) has been approved in Japan as a treatment for slowing progression of mild cognitive impairment (MCI) and mild dementia due to Alzheimer's disease (AD). The regulatory approval in Japan announced today, entitles BioArctic to a milestone of EUR 17 M.
Precision BioLogic's Factor VIII Deficient Plasma with VWF Now FDA-Cleared for Sale in U.S
Precision BioLogic Inc., a leading developer of hemostasis diagnostic products, is pleased to announce FDA 510(k) clearance and the launch of our new CRYOcheck™ Factor VIII Deficient Plasma with VWF in the U.S.
Neoss® Group has launched a new wireless intraoral scanner, NeoScan™ 2000
Neoss Group, a leading innovator in dental implant solutions, is proud to announce the fast and easy-to-use wireless intraoral scanner, NeoScan™ 2000. This follows the success of last year's launch of the NeoScan™ 1000.